Trial Profile
A phase II study of Labetuzumab-I-131 radioimmunotherapy in patients with colorectal liver metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2016
Price :
$35
*
At a glance
- Drugs Labetuzumab I 131 (Primary)
- Indications Colon cancer
- Focus Adverse reactions
- 14 Nov 2016 New trial record
- 20 Oct 2016 Results published in the Cancer